Yonsei Med J.  2013 May;54(3):707-714. 10.3349/ymj.2013.54.3.707.

Kinetics of IFN-Gamma and TNF-Alpha Gene Expression and Their Relationship with Disease Progression after Infection with Mycobacterium Tuberculosis in Guinea Pigs

Affiliations
  • 1Department of Microbiology, Yonsei University College of Medicine, Seoul, Korea. raycho@yuhs.ac
  • 2Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea.
  • 3Animal, Plant and Fisheries Quarantine and Inspection Agency, Anyang, Korea.
  • 4Basic Science Institute for Cell Damage Control, Sogang University, Seoul, Korea.
  • 5Division of Immunopathology and Cellular Immunology, International Tuberculosis Research Center, Changwon, Korea.

Abstract

PURPOSE
Guinea pig is one of the most suitable animal models for Mycobacterium tuberculosis (M. tb) infection since it shows similarities to pulmonary infection in humans. Although guinea pig shows hematogenous spread of M. tb infection into the whole body, immunological studies have mainly focused on granulomatous tissues in lungs and spleens. In order to investigate the time-course of disease pathogenesis and immunological profiles in each infected organ, we performed the following approaches with guinea pigs experimentally infected with M. tb over a 22-week post-infection period.
MATERIALS AND METHODS
We examined body weight changes, M. tb growth curve, cytokine gene expression (IFN-gamma and TNF-alpha), and histopathology in liver, spleen, lungs and lymph nodes of infected guinea pigs.
RESULTS
The body weights of infected guinea pigs did not increase as much as uninfected ones and the number of M. tb bacilli in their organs increased except bronchotracheal lymph node during the experimental period. The gene expression of IFN-gamma and TNF-alpha was induced between 3 and 6 weeks of infection; however, kinetic profiles of cytokine gene expression showed heterogeneity among organs over the study period. Histophathologically granulomatous lesions were developed in all four organs of infected guinea pigs.
CONCLUSION
Although IFN-gamma and TNF-alpha gene expression profiles showed heterogeneity, the granuloma formation was clearly observed in every organ regardless of whether the number of bacilli increased or decreased. However, this protective immunity was accompanied with severe tissue damage in all four organs, which may lead to the death of guinea pigs.

Keyword

Mycobacterium tuberculosis; pathogenesis; guinea pigs; IFN-gamma and TNF-alpha

MeSH Terms

Animals
Body Weight
*Disease Progression
Female
Gene Expression
Gene Expression Regulation
Guinea Pigs
Interferon-gamma/genetics/*metabolism
Kinetics
Liver/metabolism/pathology
Lung/metabolism/pathology
Lymph Nodes/metabolism/pathology
Mycobacterium tuberculosis
Spleen/metabolism/pathology
Tuberculosis/*genetics/pathology
Tumor Necrosis Factor-alpha/genetics/*metabolism
Tumor Necrosis Factor-alpha
Interferon-gamma

Figure

  • Fig. 1 Total body weight of guinea pigs measured after an aerosol infection with Mycobacterium tuberculosis(M. tb). After infection with M. tb, guinea pigs gained less weight compared to the uninfected control. Body weight was calculated as the mean of weights of all infected guinea pigs per time (0 and 1 week: 9, 3 wk: 7, 6 wk: 5, 10 wk: 3, 14 wk: 2 and 22 wk: 1 animal) and only one animal chosen as an uninfected control was used in this graph. The statistical analysis was not performed since the size of experimental group varied at each time point.

  • Fig. 2 TNF-α and IFN-γ synthesis in each organ of guinea pigs in response to M. tb infection. Changes in mRNA expression profiles of IFN-γ and TNF-α versus time course of infection with M. tb in each organ (lung, BTLN, spleen and liver) of guinea pigs were determined by RT-PCR analysis at each data point. (A) RT-PCR products were resolved on an agarose gel. (B) The gene expression of IFN-γ (white bar) or TNF-α (grey bar) was normalized with β-actin based on densitometry analysis. Each histogram represents mean±SD IFN-γ or TNF-α gene expression ratio to β-actin from two RT-PCR experiments. BTLN, bronchotracheal lymph node; M. tb, Mycobacterium tuberculosis.

  • Fig. 3 Growth curves of M. tb in each organ. The M. tb growth in lungs, BTLNs, spleens and livers of guinea pigs were measured after an aerosol infection with about 106 colony forming units (CFUs) per exposure. The number of mean viable CFUs in each organ at different time intervals following the infection was calculated by plating the serial dilutions of homogenates of each organ on Middlebrook 7H11 agar and counting CFUs after 14-21 days. BTLN, bronchotracheal lymph node; M. tb, Mycobacterium tuberculosis.

  • Fig. 4 Histopathological findings of uninfected or M. tb infected guinea pigs. (A-F) Lung (A) normal (40×), (B) at 1 week post-infection; mild interstitial thickening by the accumulation of inflammatory cells (40×), (C) at 3 weeks post-infection; multifocal granulomas composed of macrophages, epithelioid cells and lymphocytes develop (arrows) in the angiocentric area (40×). (D) At 14 weeks post-infection; necrotizing fibrous granulomas with caseous necrosis center of the lesion develops (arrows) (40×), (Ea and Eb) at 22 weeks post-infection (100×); bronchial tuberculosis and diffuse granulomatous inflammation are seen. (F) Acid-fast stain after 22 weeks, multiple red, rod-shaped bacilli are shown (arrows) (1000×). (G and H) BTLN. (G) Normal (40×), (H) severe necrotizing fibrous granuloma after 14 weeks (arrows) (100×). (I and J) Spleen. (I) Normal (40×), (J) the necrotic granuloma around the central arteries after 6 weeks (40×). (K and L) Liver. (K) Normal (40×), (L) the scattered granuloma in the portal area after 6 weeks (arrows) (40×). BTLN, bronchotracheal lymph node; M. tb, Mycobacterium tuberculosis.


Cited by  1 articles

Whole Blood Interferon-γ Release Assay Is Insufficient for the Diagnosis of Sputum Smear Negative Pulmonary Tuberculosis
HeeJin Park, Jung Ar Shin, Hyung Jung Kim, Chul Min Ahn, Yoon Soo Chang
Yonsei Med J. 2014;55(3):725-731.    doi: 10.3349/ymj.2014.55.3.725.


Reference

1. Tuberculosis control and research strategies for the 1990s: memo-randum from a WHO meeting. Bull World Health Organ. 1992. 70:17–21.
2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003. 163:1009–1021.
3. WHO. Global tuberculosis report 2011. Available from: http://www.who.int/tb/publications/global_report/2011/en/index.html.
4. Roche PW, Triccas JA, Winter N. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol. 1995. 3:397–401.
Article
5. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996. 348:17–24.
6. McShane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci. 2011. 366:2782–2789.
7. Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines. 2011. 10:645–658.
Article
8. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007. 13:380–387.
Article
9. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis. 2008. 21:587–595.
Article
10. Barry CE 3rd, Blanchard JS. The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol. 2010. 14:456–466.
Article
11. Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010. 182:426–432.
Article
12. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006. 368:1575–1580.
Article
13. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010. 375:2100–2109.
Article
14. Dannenberg AM Jr. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev. 2010. 23:781–794.
Article
15. Cole ST, Riccardi G. New tuberculosis drugs on the horizon. Curr Opin Microbiol. 2011. 14:570–576.
Article
16. Okada M, Kita Y. Tuberculosis vaccine development: the development of novel (preclinical) DNA vaccine. Hum Vaccin. 2010. 6:297–308.
Article
17. Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci. 2011. 32:601–606.
Article
18. Smith DW, Balasubramanian V, Wiegeshaus E. A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle. 1991. 72:223–231.
Article
19. Dannenberg AM Jr, Collins FM. Progressive pulmonary tuberculosis is not due to increasing numbers of viable bacilli in rabbits, mice and guinea pigs, but is due to a continuous host response to mycobacterial products. Tuberculosis (Edinb). 2001. 81:229–242.
Article
20. McMurray DN, Allen SS, Jeevan A, Lasco T, Cho H, Skwor T, et al. Vaccine-induced cytokine responses in a guinea pig model of pulmonary tuberculosis. Tuberculosis (Edinb). 2005. 85:295–301.
Article
21. Sugawara I, Udagawa T, Aoki T, Mizuno S. Establishment of a guinea pig model of latent tuberculosis with GFP-introduced Mycobacterium tuberculosis. Tohoku J Exp Med. 2009. 219:257–262.
Article
22. Young D. Animal models of tuberculosis. Eur J Immunol. 2009. 39:2011–2014.
Article
23. Ahmad Z, Fraig MM, Pinn ML, Tyagi S, Nuermberger EL, Grosset JH, et al. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother. 2011. 66:1560–1566.
Article
24. Grover A, Troudt J, Arnett K, Izzo L, Lucas M, Strain K, et al. Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis. Tuberculosis (Edinb). 2012. 92:105–111.
Article
25. Salgame P. Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol. 2005. 17:374–380.
Article
26. Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol. 2009. 21:378–384.
Article
27. Jeon BY, Eoh H, Ha SJ, Bang H, Kim SC, Sung YC, et al. Co-immunization of plasmid DNA encoding IL-12 and IL-18 with Bacillus Calmette-Guérin vaccine against progressive tuberculosis. Yonsei Med J. 2011. 52:1008–1015.
Article
28. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol. 2004. 22:599–623.
29. Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology. 2012. 217:363–374.
Article
30. Brighenti S, Andersson J. Local immune responses in human tuberculosis: learning from the site of infection. J Infect Dis. 2012. 205:Suppl 2. S316–S324.
Article
31. Orme IM, Cooper AM. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today. 1999. 20:307–312.
Article
32. Rahman S, Gudetta B, Fink J, Granath A, Ashenafi S, Aseffa A, et al. Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory t cells in the granulomatous lesions. Am J Pathol. 2009. 174:2211–2224.
33. Kawahara M, Nakasone T, Honda M. Dynamics of gamma interferon, interleukin-12 (IL-12), IL-10, and transforming growth factor beta mRNA expression in primary Mycobacterium bovis BCG infection in guinea pigs measured by a real-time fluorogenic reverse transcription-PCR assay. Infect Immun. 2002. 70:6614–6620.
Article
34. Cho H, Lasco TM, Allen SS, Yoshimura T, McMurray DN. Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages. Infect Immun. 2005. 73:1367–1376.
Article
35. McMurray DN. Hematogenous reseeding of the lung in low-dose, aerosol-infected guinea pigs: unique features of the host-pathogen interface in secondary tubercles. Tuberculosis (Edinb). 2003. 83:131–134.
Article
36. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med. 1993. 178:2243–2247.
Article
37. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med. 1993. 178:2249–2254.
Article
38. Ly LH, Russell MI, McMurray DN. Cytokine profiles in primary and secondary pulmonary granulomas of Guinea pigs with tuberculosis. Am J Respir Cell Mol Biol. 2008. 38:455–462.
Article
39. Ly LH, Russell MI, McMurray DN. Microdissection of the cytokine milieu of pulmonary granulomas from tuberculous guinea pigs. Cell Microbiol. 2007. 9:1127–1136.
Article
40. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun. 2002. 70:4501–4509.
Article
41. Fenhalls G, Stevens L, Bezuidenhout J, Amphlett GE, Duncan K, Bardin P, et al. Distribution of IFN-gamma, IL-4 and TNF-alpha protein and CD8 T cells producing IL-12p40 mRNA in human lung tuberculous granulomas. Immunology. 2002. 105:325–335.
Article
42. Fuller CL, Flynn JL, Reinhart TA. In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with Mycobacterium tuberculosis. Infect Immun. 2003. 71:7023–7034.
Article
43. Aung H, Toossi Z, McKenna SM, Gogate P, Sierra J, Sada E, et al. Expression of transforming growth factor-beta but not tumor necrosis factor-alpha, interferon-gamma, and interleukin-4 in granulomatous lung lesions in tuberculosis. Tuber Lung Dis. 2000. 80:61–67.
Article
44. Dai G, McMurray DN. Effects of modulating TGF-beta 1 on immune responses to mycobacterial infection in guinea pigs. Tuber Lung Dis. 1999. 79:207–214.
Article
45. Fenhalls G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun. 2000. 68:2827–2836.
Article
46. Allen SS, Cassone L, Lasco TM, McMurray DN. Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs. Infect Immun. 2004. 72:1358–1363.
Article
47. Grover A, Taylor J, Troudt J, Keyser A, Arnett K, Izzo L, et al. Kinetics of the immune response profile in guinea pigs after vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis. Infect Immun. 2009. 77:4837–4846.
Article
48. Jeevan A, Yoshimura T, Ly LH, Dirisala VR, McMurray DN. Cloning of guinea pig IL-4: reduced IL-4 mRNA after vaccination or Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2011. 91:47–56.
Article
49. Dirisala VR, Jeevan A, Bix G, Yoshimura T, McMurray DN. Molecular cloning and expression of the IL-10 gene from guinea pigs. Gene. 2012. 498:120–127.
Article
50. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008. 226:57–79.
Article
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr